VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
OGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
OGNOrganon & Co.
$13.55$3.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksOGNBalance Sheet

Organon & Co. (OGN) Balance Sheet

8Y historyFree accessUpdated daily

The company maintains a vulnerable capital structure with $8.6 billion in total debt and a significant goodwill concentration of $4.2 billion, representing 32% of the total asset base as of 2026Q1.

OGN Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets4.93B4.35B4.35B4.51B3.93B3.76B3.57B3.96B3.71B
Cash & Short-Term Investments1.12B574M675M693M706M737M12M319M244M
Cash Only1.12B574M675M693M706M737M12M319M244M
Short-Term Investments000000000
Accounts Receivable1.38B1.43B1.49B1.86B1.61B1.51B1.41B1.57B1.59B
Days Sales Outstanding86.0584.1484.99108.2294.9487.5478.5173.8359.47
Inventory1.37B01.32B1.31B1B915M913M1.07B994M
Days Inventory Outstanding136.24-179.38190.84159.59140.21157.27171.9177.31
Other Current Assets1.06B2.35B861M643M616M596M1.24B992M883M
Total Non-Current Assets8.06B8.52B8.75B7.55B7.02B6.92B6.54B6.59B6.78B
Property, Plant & Equipment1.28B01.32B1.36B1.23B1.2B1.01B762M651M
Fixed Asset Turnover6.43x-4.83x4.62x5.01x5.24x6.44x10.21x15.02x
Goodwill4.15B4.15B4.68B4.6B4.6B4.6B4.6B4.6B4.6B
Intangible Assets1.1B1.13B1.41B533M649M651M503M569M812M
Long-Term Investments0027M000000
Other Non-Current Assets1.53B3.23B361M250M272M464M421M659M714M
Total Assets13B12.87B13.1B12.06B10.96B10.68B10.11B10.55B10.49B
Asset Turnover0.47x0.48x0.49x0.52x0.56x0.59x0.65x0.74x0.93x
Asset Growth %14.35%-1.79%8.65%10.07%2.57%5.66%-4.16%0.51%-
Total Current Liabilities2.5B2.39B2.72B2.92B2.51B2.6B2.67B1.34B1.54B
Accounts Payable983M952M1.15B1.31B1.13B1.38B259M258M289M
Days Payables Outstanding128.7121.75156.56190.7180.11211.7744.6141.4122.48
Short-Term Debt16M56M64M55M57M55M8M48M115M
Deferred Revenue (Current)00000000322M
Other Current Liabilities1.5B1.3B1.37B1.34B1.14B975M2.12B793M6M
Current Ratio1.97x1.82x1.60x1.54x1.56x1.45x1.33x2.95x2.40x
Quick Ratio1.42x1.82x1.11x1.09x1.17x1.10x0.99x2.15x1.76x
Cash Conversion Cycle93.6-107.81108.3774.4215.98191.16204.32114.3
Total Non-Current Liabilities9.59B9.72B9.91B9.21B9.34B9.59B1.95B2.17B2.6B
Long-Term Debt8.55B8.64B8.86B8.75B8.9B9.13B070M34M
Capital Lease Obligations116M116M112M125M150M184M23M68M0
Deferred Tax Liabilities244M57M74M47M19M4M128M139M149M
Other Non-Current Liabilities984M924M865M287M261M279M1.8B1.9B2.57B
Total Liabilities12.09B12.12B12.63B12.13B11.85B12.19B4.62B3.51B4.15B
Total Debt8.57B8.8B9.04B8.93B9.11B9.36B31M186M149M
Net Debt7.45B8.23B8.36B8.24B8.41B8.63B19M-133M-95M
Debt / Equity9.49x11.70x19.14x---0.01x0.03x0.02x
Debt / EBITDA5.56x5.37x5.13x5.71x4.75x4.44x0.01x0.04x0.03x
Net Debt / EBITDA4.84x5.02x4.74x5.27x4.38x4.09x0.01x-0.03x-0.02x
Interest Coverage1.97x1.84x2.55x2.28x3.66x6.93x474.50x593.50x-
Total Equity903M752M472M-70M-892M-1.51B5.49B7.04B6.35B
Equity Growth %618.73%59.32%774.29%92.15%40.85%-127.49%-22.02%10.82%-
Book Value per Share3.432.881.82-0.27-3.50-5.9521.6427.7925.08
Total Shareholders' Equity903M752M472M-70M-892M-1.51B5.49B7.04B6.35B
Common Stock3M3M3M3M3M3M6.11B7.95B7.26B
Retained Earnings1.25B1.11B1.01B443M-331M-998M000
Treasury Stock000000000
Accumulated OCI-539M-527M-649M-541M-564M-513M-622M-914M-908M
Minority Interest000000000

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

High Debt Service Burden

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Equity Base Remains Precariously Thin

According to the most recent quarterly financial data, Organon's equity base has shown extreme volatility, fluctuating from a deficit of $70 million in 2023Q4 to a modest $903 million by 2026Q1, underscoring the persistent fragility of the company's capital structure amidst ongoing operational headwinds.

The erratic movement in equity suggests that the company's net income generation is insufficient to consistently build book value, leaving the balance sheet highly sensitive to any impairment or non-operating charge. Investors should monitor whether this trend of thin capitalization persists, as it limits the company's financial flexibility during periods of market volatility.

Leverage Ratios Signal Financial Strain

Based on reported figures, Organon maintains a significant debt load of $8.6 billion as of 2026Q1, with the debt-to-equity ratio reaching as high as 181.54 in 2024Q1, which indicates that the company's capital structure is heavily reliant on external financing rather than internal equity accumulation.

The high leverage ratio suggests that a substantial portion of the company's operating cash flow is likely diverted toward interest obligations, potentially starving the business of necessary R&D investment. This reliance on debt warrants further investigation into the maturity profile and the company's ability to refinance under potentially less favorable credit conditions.

Goodwill Concentration Masks Asset Quality

As reported in financial statements, goodwill accounts for approximately $4.2 billion of the $13.0 billion total asset base in 2026Q1, representing a significant portion of the company's valuation that is inherently subjective and susceptible to future impairment charges if segment performance continues to decline.

The heavy reliance on intangible assets suggests that the company's tangible asset base is relatively small, which may limit the collateral available for future financing needs. Analysts should consider the risk that these intangible assets may not provide the expected long-term economic benefits if the legacy brand portfolio faces accelerated competitive erosion.

Cash Buffers Remain Modestly Adequate

Based on the latest quarterly filings, Organon's cash position of $1.1 billion in 2026Q1, combined with a current ratio of 1.97, suggests a temporary improvement in short-term liquidity compared to the 1.54 ratio observed in 2023Q4, providing a limited buffer against immediate operational shocks.

While the current ratio appears to have stabilized, the absolute cash balance remains small relative to the company's total debt obligations. This liquidity profile suggests that the company may struggle to maintain its current pace of acquisitions and debt service if working capital requirements become more demanding in the coming quarters.

OGN — Frequently Asked Questions

Quick answers to the most common questions about buying OGN stock.

What are the total assets of Organon & Co. (OGN)?

As of 2025, Organon & Co. (OGN) had total assets of $12.87B including $4.35B in current assets.

How much debt does Organon & Co. (OGN) have?

Organon & Co. (OGN) carries total debt of $8.80B, offset by $574.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Organon & Co.?

Organon & Co. (OGN) has total shareholders' equity (book value) of $752.0M ($2.88 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Organon & Co.'s current ratio and liquidity?

Organon & Co. (OGN) reported a current ratio of 1.82x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.